Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening
Background and objectivesThe propensity of human papillomavirus (HPV) to cause cervical cancer is linked to specific genotypes that vary in carcinogenicity. This study aims to provide insight into the most prevalent HPV genotypes in Latvia among women participating in cervical cancer screening.Mater...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1584677/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849426749269475328 |
|---|---|
| author | Anna Stasulane Anna Stasulane Justine Grundmane Justine Grundmane Kristiana Sulte Kristiana Sulte Janis Stasulans Janis Stasulans Solvita Cernavska Solvita Cernavska Laura Smite Laura Smite |
| author_facet | Anna Stasulane Anna Stasulane Justine Grundmane Justine Grundmane Kristiana Sulte Kristiana Sulte Janis Stasulans Janis Stasulans Solvita Cernavska Solvita Cernavska Laura Smite Laura Smite |
| author_sort | Anna Stasulane |
| collection | DOAJ |
| description | Background and objectivesThe propensity of human papillomavirus (HPV) to cause cervical cancer is linked to specific genotypes that vary in carcinogenicity. This study aims to provide insight into the most prevalent HPV genotypes in Latvia among women participating in cervical cancer screening.Materials and methodsThe prevalence data presented in this study were derived from routine screening. The data were collected during the first two years of the reorganized screening program, from 1 July 2022 to 1 July 2024, which for the first time included HPV genotyping as a primary screening method in women aged 30–70. Testing was performed in an accredited laboratory using a commercial kit capable of detecting 14 HPV genotypes.ResultsThe overall prevalence among 30–70-year-old women participating in cervical cancer screening in Latvia was 12.04%. HPV 16 was the most prevalent HPV genotype, followed by HPV 68, 31, 66, 52, 56, 51, 45, 33, 39, 18, 58, 59, and 35. Across all age categories, single infections were the most prevalent—81.82% of women tested positive for only one HPV genotype, with an average of 1.23 genotypes per positive sample. The prevalence of both single and co- infections tended to decrease with age, except for a slight increase in the oldest age group, women aged 60–70. There was a significant difference in the overall HPV infection prevalence across age groups.ConclusionsThese results provide valuable epidemiological data that can inform cervical cancer screening, prognosis, HPV vaccine implementation targeting region-specific genotypes, and ongoing monitoring of genotype distribution. |
| format | Article |
| id | doaj-art-ec0208aecc96495484b11cc3600a118d |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ec0208aecc96495484b11cc3600a118d2025-08-20T03:29:15ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15846771584677Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screeningAnna Stasulane0Anna Stasulane1Justine Grundmane2Justine Grundmane3Kristiana Sulte4Kristiana Sulte5Janis Stasulans6Janis Stasulans7Solvita Cernavska8Solvita Cernavska9Laura Smite10Laura Smite11Faculty of Medicine, Riga Stradins University, Riga, LatviaE. Gulbis Laboratory, Riga, LatviaE. Gulbis Laboratory, Riga, LatviaFaculty of Medicine and Life Sciences, University of Latvia, Riga, LatviaFaculty of Medicine, Riga Stradins University, Riga, LatviaRiga Maternity Hospital, Riga, LatviaFaculty of Medicine, Riga Stradins University, Riga, LatviaE. Gulbis Laboratory, Riga, LatviaFaculty of Medicine, Riga Stradins University, Riga, LatviaE. Gulbis Laboratory, Riga, LatviaE. Gulbis Laboratory, Riga, LatviaFaculty of Medicine and Life Sciences, University of Latvia, Riga, LatviaBackground and objectivesThe propensity of human papillomavirus (HPV) to cause cervical cancer is linked to specific genotypes that vary in carcinogenicity. This study aims to provide insight into the most prevalent HPV genotypes in Latvia among women participating in cervical cancer screening.Materials and methodsThe prevalence data presented in this study were derived from routine screening. The data were collected during the first two years of the reorganized screening program, from 1 July 2022 to 1 July 2024, which for the first time included HPV genotyping as a primary screening method in women aged 30–70. Testing was performed in an accredited laboratory using a commercial kit capable of detecting 14 HPV genotypes.ResultsThe overall prevalence among 30–70-year-old women participating in cervical cancer screening in Latvia was 12.04%. HPV 16 was the most prevalent HPV genotype, followed by HPV 68, 31, 66, 52, 56, 51, 45, 33, 39, 18, 58, 59, and 35. Across all age categories, single infections were the most prevalent—81.82% of women tested positive for only one HPV genotype, with an average of 1.23 genotypes per positive sample. The prevalence of both single and co- infections tended to decrease with age, except for a slight increase in the oldest age group, women aged 60–70. There was a significant difference in the overall HPV infection prevalence across age groups.ConclusionsThese results provide valuable epidemiological data that can inform cervical cancer screening, prognosis, HPV vaccine implementation targeting region-specific genotypes, and ongoing monitoring of genotype distribution.https://www.frontiersin.org/articles/10.3389/fonc.2025.1584677/fullHPVcervical cancergenotypesdistributionLatvia |
| spellingShingle | Anna Stasulane Anna Stasulane Justine Grundmane Justine Grundmane Kristiana Sulte Kristiana Sulte Janis Stasulans Janis Stasulans Solvita Cernavska Solvita Cernavska Laura Smite Laura Smite Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening Frontiers in Oncology HPV cervical cancer genotypes distribution Latvia |
| title | Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening |
| title_full | Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening |
| title_fullStr | Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening |
| title_full_unstemmed | Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening |
| title_short | Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening |
| title_sort | prevalence of human papillomavirus genotypes in latvia among women participating in cervical cancer screening |
| topic | HPV cervical cancer genotypes distribution Latvia |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1584677/full |
| work_keys_str_mv | AT annastasulane prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT annastasulane prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT justinegrundmane prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT justinegrundmane prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT kristianasulte prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT kristianasulte prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT janisstasulans prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT janisstasulans prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT solvitacernavska prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT solvitacernavska prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT laurasmite prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening AT laurasmite prevalenceofhumanpapillomavirusgenotypesinlatviaamongwomenparticipatingincervicalcancerscreening |